A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 79, Issue 4, 2017, Pages 673-680

  Tolcher, Anthony W ^a   Berlin, Jordan D ^b   Cosaert, Jan ^c,e   Kauh, John ^c   Chan, Emily ^b   Piha Paul, Sarina A ^d   Amaya, Alex ^a   Tang, Shande ^c   Driscoll, Kyla ^c   Kimbung, Richard ^c   Kambhampati, S R Prasad ^c   Gueorguieva, Ivelina ^c   Hong, David S ^d  

^a South Texas Accelerated Research Therapeutics   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MERCK KGAA   (Germany)

Author keywords

Monoclonal antibody; Solid tumors; TGF ; TGF receptor; Therapy resistance

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GAMMA GLUTAMYLTRANSFERASE; LY 3022859; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; TROPONIN; UNCLASSIFIED DRUG; CYTOKINE; LY3022859; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PAIN; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CARCINOMA; EWING SARCOMA; FAINTNESS; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; INFUSION RELATED REACTION; INTESTINE OBSTRUCTION; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECTUM CANCER; SIDE EFFECT; SMALL CELL LUNG CANCER; SMALL INTESTINE OBSTRUCTION; SOLID TUMOR; TREATMENT DURATION; TUMOR XENOGRAFT; UTERUS SARCOMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85014644572     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-017-3245-5     Document Type: Article

References (18)

1. Massagué J (2008) TGFβ in cancer. Cell 134:215–230
2. Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-β and the immune response: implications for anticancer therapy. Clin Cancer Res 13:5262–5270
3. Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078–2093
4. Inman GJ (2011) Switching TGFB from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 21:93–99
5. Teicher BA (2007) Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 13:6247–6251
6. Levy L, Hill CS (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17:41–58
7. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10:554–567
8. Prud’homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87:1077–1091
9. Massagué J, Gomis RR (2006) The logic of TGFβ signaling. FEBS Lett 580:2811–2820
10. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, Burtrum D, Wang S, Surguladze D, Ng S, Griffith H, Balderes P, Doody J, Schwartz JD, Youssoufian H, Rowinsky EK, Ludwig DL, Witte L, Zhu Z, Wu Y (2010) Anti–transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16:1191–1205
11. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapartra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig S, Schmaus S, Heinrichs H, Schlingensiepen KH; Trabedersen Glioma Study Group (2011) Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 13:132–142
12. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, Dezube BJ, Hsu FJ, Reiss M, Berzofsky JA (2008) Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26(15 suppl):abstract 9028
13. Ahnert J, Baselga J, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, Lahn MMF, Pillay S, Holdhoff M, Blakeley JO, Carducci MA (2011) First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol 29(15 suppl):abstract 3011
14. Lonning S, Mannick J, McPherson JM (2011) Antibody targeting of TGF-β in cancer patients. Curr Pharm Biotechnol 12:2176–2189
15. Oettle H, Hilbig A, Seufferlein T, Tsianakas A, Luger T, Schmid RM, von Wichert G, Endlicher E, Garbe C, Kaehler KK, Hauschild A, Enk A, Kiessling P, Schmaus S, Heinrichs H, Schlingensiepen K (2011) Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. J Clin Oncol 29(15 suppl):abstract 2513
16. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium (2007) Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323–333
17. Lahn M, Kloeker S, Berry BS (2005) TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 14:629–643
18. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79:1236–1243